Merck KGaA picks up another anticancer bispecific from F-star

Merck KGaA has exercised its option on a preclinical F-star Therapeutics immuno-oncology asset. The action, which F-star said came ahead of schedule, comes one year after Merck KGaA took up its option on another early-stage F-star molecule.